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Background. The objective of this study was to determine whether treatment with the nonselective nonsteroidal anti-
inflammatory drug (NSAID) indomethacin slows cognitive decline in patients with Alzheimer’s disease (AD). Methodology/
Principal Findings. This double-blind, randomized, placebo-controlled trial was conducted between May 2000 and
September 2005 in two hospitals in the Netherlands. 51 patients with mild to moderate AD were enrolled into the study.
Patients received 100 mg indomethacin or placebo daily for 12 months. Additionally, all patients received omeprazole. The
primary outcome measure was the change from baseline after one year of treatment on the cognitive subscale of the AD
Assessment Scale (ADAS-cog). Secondary outcome measures included the Mini-Mental State Examination, the Clinician’s
Interview Based Impression of Change with caregiver input, the noncognitive subscale of the ADAS, the Neuropsychiatric
Inventory, and the Interview for Deterioration in Daily life in Dementia. Considerable recruitment problems of participants
were encountered, leading to an underpowered study. In the placebo group, 19 out of 25 patients completed the study, and 19
out of 26 patients in the indomethacin group. The deterioration on the ADAS-cog was less in the indomethacin group
(7.867.6), than in the placebo group (9.3610.0). This difference (1.5 points; CI 24.5–7.5) was not statistically significant, and
neither were any of the secondary outcome measures. Conclusions/Significance. The results of this study are inconclusive
with respect to the hypothesis that indomethacin slows the progression of AD. Trial Registration. ClinicalTrials.gov
NCT00432081
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INTRODUCTION
Early indications that inflammation plays an important role in the
pathogenesis of Alzheimer’s disease (AD) emerged in 1982, when
complement factors were found in senile plaques. [1] Many studies
followed that supported the inflammatory hypothesis, and
evidence accumulated that anti-inflammatory drugs, in particular
nonsteroidal anti-inflammatory drugs (NSAIDs) would either
prevent, postpone or treat AD. [2] However, 25 years later, there
is still no clinical evidence that NSAIDs have an effect in AD
patients, nor is there incontrovertible evidence of the contrary.
In a small randomized controlled trial, the traditional NSAID
indomethacin appeared to protect AD patients from cognitive
decline. [3] Another small randomized controlled trial studying
the effect of diclofenac/misoprostol in AD, found a nonsignificant
trend of more advanced deterioration in the placebo group than in
the diclofenac/misoprostol group. [4] A large randomized
controlled trial with naproxen (440 mg/d) could not confirm the
earlier observed trends. [5] Both pilot studies were hampered by
high withdrawal rates in the treatment groups due to side effects.
Low-dose naproxen was reasonably well tolerated.
The side effects of NSAIDs, e.g. gastrointestinal toxicity, have
always been a major concern that limited their use. It was
suggested that the beneficial actions of NSAIDs are linked to their
ability to inhibit cyclooxygenase-2 (COX-2), while their side effects
result from inhibition of COX-1. [6] However, randomized
controlled trials with COX-2 selective NSAIDs (rofecoxib,
nimesulide, and celecoxib) failed to show an effect on the
progression of AD. [5,7–9] Consequently, the traditional nonse-
lective NSAIDs regained interest.
Apart from the promising, but never replicated, results of the
initial indomethacin trial, there are also in vitro and animal model
studies that support a possible therapeutic effect. Indomethacin
inhibited amyloid b (Ab)-induced neurotoxicity, [10–12] and
decreased the production of Ab-protein, interleukin-6, interleukin-
1, nitric oxide, and prostaglandin E2 in a variety of cultured cells.
[13–18] Furthermore, indomethacin was found to have anti-
amyloidogenic effects in vitro; The formation of Ab fibrils was
dose-dependently inhibited by indomethacin. [19] In rats,
indomethacin attenuated microglial infiltration, and improved
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mouse-model of AD-like amyloidosis (Tg2576), indomethacin
suppressed brain levels of prostaglandins, [22] and reduced Ab
levels in cortex and hippocampus. [22,23] This amyloid burden
lowering effect was confirmed by other investigators using a
combination of indomethacin and vitamin E to treat Tg2576 mice.
[24]
Supported by these data, particularly by the prior trial that
suggested a therapeutic benefit as well as by its potential Ab
lowering effect, we hypothesized that indomethacin may retard the
clinical progression of AD.
METHODS
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Protocol S1 (Dutch
version), Protocol S2 (English version) and Checklist S1.
Participants
Patients were recruited from May 2000 to August 2004 at the
Department of Neurology and at the Memory Clinic, Department
of Geriatric Medicine of the Radboud University Nijmegen
Medical Center, and at the Memory clinic of the Department of
Geriatric Medicine, Rijnstate Hospital, Arnhem, The Nether-
lands. Patients were eligible if they met the NINCDS/ADRDA
criteria for the clinical diagnosis of probable AD, [25] had mild or
moderate dementia as measured by a Mini-Mental State
Examination (MMSE) [26] score between 10 and 26 inclusive,
and were living at home or in a home for the elderly. Patients had
to be supported by a reliable caregiver, who accompanied them to
each clinic visit in order to provide information about the patient’s
functional status, and who would ensure that the participants took
their test medication.
Patients were excluded if they had a history or current evidence
of peptic ulceration; history of gastric surgery or gastrointestinal
bleeding; severe and unstable cardiovascular disease; severe
pulmonary disease; renal failure (serum creatinine greater than
200 mmol/l); clinically significant liver disease (plasma aspartate
and alanine aminotransferase levels three times the upper limit of
normal); poorly controlled diabetes mellitus; hypersensitivity to
NSAIDs or aspirin; alcohol abuse; or advanced, severe and
unstable disease of any type (other than AD), that might interfere
with evaluations during the study, including a medical condition
which should be expected to progress, recur, or change to such an
extent that it might bias the assessment of the clinical or mental
status of the patient, or put the patient at special risk. Also, patients
taking the following concomitant medications were excluded,
because of a possible interaction with indomethacin; aspirin,
coumarin derivatives, angiotensin converting enzyme inhibitors,
loop diuretics, and long-term use of other NSAIDs or corticoste-
roids (more than two months immediately before study entry).
Intake of the following medication was not allowed during the
study because of a possible effect on cognition; estrogen
replacement therapy, deprenyl, vitamin E, neuroleptics and
anticholinergic medication. Patients using stable doses of cholin-
esterase inhibitors were eligible, with the provision that the dose
should not be changed during the study. Cholinesterase inhibitors
could not be initiated during the study.
Ethics
At both study sites, approval of the local institutional review
board to perform the study was received. Informed consent was
obtained from each patient and their legally acceptable represen-
tative.
Interventions
The study was a one-year, randomized, double-blinded, placebo-
controlled bicenter trial. After screening, patients were randomly
assigned to receive 50 mg indomethacin twice daily or placebo
twice daily for one year. In addition, patients in both treatment
groups received omeprazole 20 mg once daily, to prevent
gastrointestinal side effects.
Objectives
We tested whether indomethacin would have an effect on
cognitive and behavioral dysfunction, as well as dysfunction of
the activities of daily living, in patients with mild to moderate AD.
Outcomes
Efficacy was primarily assessed by the cognitive subscale of the AD
Assessment Scale (ADAS-cog), [27] an instrument that evaluates
memory, language, attention, reasoning, orientation, and praxis
(range 0 to 70). Secondary outcome measures included the
MMSE, [26] the Clinician’s Interview Based Impression of
Change with caregiver input (CIBIC+), [28] the noncognitive
subscale of the ADAS (ADAS-noncog), [27] the Neuropsychiatric
Inventory (NPI), [29,30] including the NPI caregiver distress scale
(NPI-D), [31] and the Interview for Deterioration in Daily life in
Dementia (IDDD). [32] The IDDD is a caregiver-based measure,
which consists of 20 concretely worded items that reflect the
initiative to perform, and the actual performance of self-care and
more complex activities.
Cognitive and behavioral assessments were performed at
baseline, and at weeks 26 and 52. Safety assessments included
vital signs and the recording and rating of any adverse event by the
investigator (weeks 4, 8, 12, 26, 38, and 52), physical examination
(baseline, week 26, and 52), and routine hematology and chemistry
blood tests (baseline, week 4, 8, 26, and 52).
Sample size
The primary hypothesis tested was that indomethacin would be
superior to placebo in retarding cognitive decline as measured on
the ADAS-cog after one year of treatment. We aimed at 80%
power to detect a 3-point difference in the change in ADAS-cog
score after one year between patients who received indomethacin
and those who received placebo. ADAS-cog data from previous
studies were used in the power calculations for the initial trial, and
an SD of 7 was assumed. This yielded a estimated sample size of
67 to be evaluated per group. Since an overall dropout rate of 20%
was anticipated, the required sample size was 80 patients per
group.
Randomization – Sequence generation
The statistician provided computer-generated lists of random
numbers allocating patients in a 1:1 ratio to receive indomethacin
or placebo. For each center, a separate randomization list was
provided.
Randomization – Allocation concealment
Randomization codes were held by the pharmacy of the Radboud
University Nijmegen Medical Center that labeled and dispensed
all trial medication. Allocation was concealed from all investigators
and patients.
Randomization – Implementation
Eligible patients were allocated to a randomization number in the
same order they were enrolled in the trial at both trial sites. At
Indomethacin in Alzheimer’s
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or placebo) by the pharmacy, labeled with their randomization
number.
Blinding
The indomethacinand placebo tablets wereofidentical appearance.
Neitherthe patients northe investigators knewwhich treatmentthey
receivedordispensed.Theblindingprocessremainedcompleteuntil
alldatawasenteredinthetrialdatabaseandtheaccuracyofthedata
and the database was confirmed. Afterward, the database was
forwarded to the statistician for analysis.
Statistical methods
The changes from baseline in the groups were compared using
analysis of covariance with the baseline results of each assessment
as a covariate. In an additional analysis, gender and age were
added as covariates. Two-sided p values and 95% confidence
intervals were calculated. The primary efficacy analysis was
conducted on the observed values. In addition, the last observation
carried forward (LOCF) approach was used.
RESULTS
Participant flow and recruitment
Figure 1 illustrates the flow of patients through the study protocol.
The study was discontinued prematurely after four years, due to
difficulties with the enrollment of patients into the study. Based on
an inclusion rate of approximately thirteen patients per year, eight
more years of enrollment would have been necessary to complete
this study. Taking into account scientific, organizational, and
financial reasons, the decision was made to discontinue the study.
Eventually, fifty-one patients were included in the trial, about one-
thirds of the number originally anticipated. Most patients were
enrolled at the Memory Clinic, Department of Geriatric Medicine
of the Radboud University Nijmegen Medical Center (n=46),
with an inclusion rate of one out of every five to six patients
diagnosed with AD. The remainder of patients was enrolled at the
outpatient clinic of the Department of Neurology of the Radboud
University Nijmegen Medical Center (n=3), and at the Depart-
ment of Geriatric Medicine of the Rijnstate Hospital, Arnhem
(n=2).
Numbers analyzed
Twenty-five patients were randomly assigned to the placebo
group, and twenty-six patients to the indomethacin group.
Completion rates were 19 of 25 patients (76%) in the placebo
group, and 19 of 26 patients (73%) in the indomethacin group.
One patient in the indomethacin group discontinued the study in
week 48 due to caregiver issues, but completed all week 52
evaluations. The predominant reasons for premature study
discontinuation were adverse events (n=6) in the indomethacin
group, and withdrawal of consent (n=2) in the placebo group.
None of the patients that withdrew from the study due to adverse
events did complete their follow-up assessments, however all other
available assessment data were included in the analysis.
Baseline data
Treatment groups were similar with respect to demographic and
baseline clinical characteristics, except for gender distribution
(table 1); in the placebo group 24% of patients were male, and in
the indomethacin group 46% of patients. No significant differences
were found between baseline assessment scores. Nevertheless,
baseline NPI, NPI-D, and ADAS-noncog scores were higher in the
indomethacin group, suggesting that patients in this group had
more behavioral problems.
Outcomes, estimation, and ancillary analyses
The effect of treatment on primary and secondary outcome
measures is shown in table 2. The decrease in mean ADAS-cog
score after one year of therapy was 1.5 points less in the
indomethacin group (7.867.6) compared to the placebo group
(9.3610.0), however this was not statistically significant (CI 24.5–
7.5). When using the LOCF approach to analyze the difference in
change in ADAS-cog score, or when gender and age were
included as covariate in the analysis, the results were similar to the
primary analysis (data not shown).
The decline of secondary outcome measures after six months or
one year of treatment did not show statistically significant
differences between groups either (table 2). Additional analysis,
using the LOCF approach, showed similar results.
Adverse Events
Blood test abnormalities, abnormalities found during physical
examination, and adverse events reported on case report forms
were grouped into categories for analysis. Adverse events that
occurred in at least two patients in either treatment group are
listed in table 3. Patients in the indomethacin group had more
frequent adverse events. Dyspepsia, epigastic pain, or abdominal
distress or pain, were reported more frequently in the placebo
group (n=3), than in the indomethacin group (n=1). In both
groups, there were no reports of serious gastrointestinal adverse
events, such as gastroenteritis, ulceration or bleeding. Nausea,
dizziness, and hyperglycemia were more common in the
indomethacin group, whereas diarrhea, constipation, and head-
ache, were more common in the placebo group. Weight loss,
defined as 5 percent or more loss of body weight, was seen in three
patients in the indomethacin group, and in one patient in the
placebo group. New cases of hypertension were reported more
frequently in the indomethacin group (5 out of 22 non-
hypertensive patients at baseline; 23%), than in the placebo group
(2 out of 18 non-hypertensive patients at baseline; 11%). Despite
these cases of elevated blood pressure, the change in mean arterial
pressure (MAP) during the trial was not significantly different
between groups; MAP increased 2.5610.6 (mean6SD) mmHg in
the indomethacin group, and decreased 1.269.5 mmHg in the
placebo group (p=0.20).
Serious adverse events were also more common in the
indomethacin group (n=5) than in the placebo group (n=1;
table 4), and reason for study withdrawal (table 4). In the
indomethacin group, blood tests revealed a considerable elevation
of creatinine levels (.1.5 times the upper limit of normal) in three
patients, without clinical symptoms. All three patients had
abnormal creatinine clearance rates before entering the trial,
and one of these patients had a history of nephrectomy. After
discontinuation of the study, serum creatinine levels returned to
their previous levels. Blood tests also revealed increased levels (.3
times the upper limit of normal) of alanine aminotransferase, and
aspartate aminotransferase in one patient in the indomethacin
group, without clinical symptoms. Liver function tests normalized
within four weeks after study discontinuation. Nine days after
enrollment in the study, one patient in the indomethacin group
had a lacunar stroke. Evaluation after four months of recovery
revealed only minor disabilities (increased memory impairment
and irritability). Death occurred in one patient in the placebo
group after 38 weeks of study participation. The cause of death of
this patient is unknown.
Indomethacin in Alzheimer’s
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Interpretation
In this study, indomethacin 50 mg twice daily did not show any
statistically significant effects on the progression of dementia in
patients with mild to moderate AD during a 1-year period, as
measured by testing of cognition, behavior, and activities of daily
living, and by overall clinical global impression.
Although our study included more patients than the earlier trials
with indomethacin and diclofenac/misoprostol, the number of
included patients was still too small. [3,4] Thus, the study was
clearly underpowered, resulting in very wide confidence intervals;
The confidence interval for the ADAS-cog was 12 points (range –
4.5 to 7.5). This means that the difference between the groups
should have been at least 6 points to reach statistical significance.
Generalizability
The enrollment of patients was hampered by the extensive
exclusion criteria, especially the exclusion of patients using aspirin,
angiotensin converting enzyme inhibitors or loop diuretics. The
institutional review board specifically imposed this criterion, since
interaction of these drugs with indomethacin might aggravate the
occurrence of side effects of indomethacin. Not only did patient
enrollment suffer from these strict criteria, it is also responsible for
another limitation of the study; Our study population was a highly
selected group of AD patients, with no or minor cardiovascular
comorbidity, and thus not representative of the average AD
population.
Overall evidence
By its nature our study cannot prove that anti-inflammatory drugs
in general and indomethacin in particular are ineffective.
However, the study outcome is consistent with earlier trials that
investigated prednisone, hydroxychloroquine, and various selec-
tive and non-selective NSAIDs in similar designs; All these studies
failed to demonstrate a beneficial effect on disease progression.
[4,5,7–9,33,34] These failures may have been due to the
pharmacokinetic or pharmacological properties of the drugs being
Figure 1. Trial profile.
doi:10.1371/journal.pone.0001475.g001
Table 1. Baseline characteristics of the study population by
treatment group.
......................................................................
Characteristics Placebo (n=25)
Indomethacin
(n=26)
Men/women 6/19 12/14
Age (SD), years 72.2 (9.0) 72.7 (6.9)
Education level (SD), range 1 to 5* 2.7 (0.9) 2.4 (1.3)
$1 APOE e4 allele, n (%) 11 (44%) 13 (50%)
Disease duration (SD), months 31.1 (19.6) 32.9 (17.4)
Use of cholinesterase inhibitor, n (%) 2 (8,0%) 2 (7.7%)
MMSE score (SD) 20.2 (3.9) 19.1 (4.1)
ADAS-cog score (SD) 19.7 (8.8) 20.2 (8.3)
ADAS-noncog score (SD) 2.8 (2.7) 3.5 (3.6)
NPI score (SD) 7.1 (6.7) 11.2 (12.0)
NPI-D score (SD) 5.6 (4.5) 7.7 (7.3)
IDDD score (SD) 21.2 (12.8) 22.8 (13.7)
*level 1 is primary school only; level 5 is university level.
MMSE=Mini-Mental State Examination; ADAS-cog=cognitive subscale of the
Alzheimer’s Disease Assessment Scale; ADAS-noncog=noncognitive subscale
of the ADAS; NPI=Neuropsychiatric Inventory; NPI-D=caregiver distress scale
of the NPI; IDDD=Interview for Deterioration in Daily life in Dementia.
doi:10.1371/journal.pone.0001475.t001
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treatment will ever be efficacious in treating symptomatic AD.
Although they may have preventive effects, they may no longer be
effective in patients with established disease.
Indomethacin in combination with omeprazole was reasonably
well tolerated in this elderly population. There were no serious
gastrointestinal tract events. Dyspepsia, epigastic pain, or abdom-
inal distress or pain were more common in the placebo group, and
may have been caused by omeprazole, and not by indomethacin.
However, elderly patients should be carefully monitored when
using indomethacin. Blood pressure should be checked regularly,
and blood tests must be done before and during indomethacin
treatment. In patients with elevated creatinine clearance, the
administration of indomethacin should be avoided.
In conclusion, the results of this study are inconclusive with
respect to the hypothesis that indomethacin slows the progression
of AD. Owing to its limited statistical power, this study does not
alter the conclusions from earlier trials that NSAIDs do not appear
to be effective in altering the progression of symptoms in AD.
Thus, treatment of AD patients with indomethacin should
Table 2. Mean change from baseline of outcome measures, and difference in scores between the placebo and indomethacin
group, after six months and one year of treatment.
..................................................................................................................................................
Placebo group mean change from
baseline (SD)
Indomethacin group mean change from
baseline (SD) Difference between groups* (95% CI)
Measure 6 months (n=23) 1 year (n=19) 6 months (n=20) 1 year (n=19) 6 months 1 year
ADAS-cog 3.9 (4.5) 9.3 (10.0) 4.8 (5.8) 7.8 (7.6) 20.9 (24.1–2.2) 1.5 (24.5–7.5)
ADAS-noncog 20.3 (1.5) 1.6 (4.2) 1.5 (4.1) 3.8 (6.7) 21.8 (23.9–0.2) 22.8 (26.7–1.1)
MMSE 22.4 (3.6) 25.4 (5.5) 22.3 (3.2) 23.4 (4.3) 0.1 (21.9–2.1) 1.6 (21.6–4.8)
NPI 20.3 (4.9) 9.4 (14.0) 1.7 (14.0) 3.2 (18.1) 23.6 (210.1–2.9) 4.6 (26.6–15.8)
NPI-D 20.9 (3.5) 6.5 (8.8) 0.7 (6.4) 1.4 (8.3) 22.2 (25.4–1.0) 4.6 (21.3–10.5)
IDDD 10.4 (8.3) 18.2 (14.8) 9.5 (14.4) 19.4 (13.8) 0.8 (26.4–8.0) 21.5 (211.0–8.0)
CIBIC+ 5.3 (0.7) 5.7 (0.7) 5.1 (0.8) 5.6 (0.8) 0.2 (20.2–0.6) 0.1 (20.3–0.5)
*differences, adjusted for baseline (analysis of covariance).
Negative change in scores from baseline indicates improvement, with the exception of the MMSE score (positive change indicates improvement), and the CIBIC+
(higher score means worse compared to baseline).
Positive difference between groups means in favor of the indomethacin group, for all measures.
ADAS-cog=cognitive subscale of the Alzheimer’s Disease Assessment Scale; ADAS-noncog=noncognitive subscale of the ADAS; MMSE=Mini-Mental State
Examination; NPI=Neuropsychiatric Inventory; NPI-D=caregiver distress scale of the NPI; IDDD=Interview for Deterioration in Daily life in Dementia; CIBIC+=Clinician’s
Interview Based Impression of Change with caregiver input.
doi:10.1371/journal.pone.0001475.t002
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Table 3. Adverse events that occurred in at least two patients in either treatment group.
..................................................................................................................................................
Adverse event Placebo and omeprazole (n=25) Indomethacin and omeprazole (n=26)
Nausea 02
Diarrhea or constipation 3 2
Dyspepsia, epigastric or abdominal pain 3 1
Weight loss ($ 5% during the study) 1 3
Headache 20
Dizziness 13
Hyperglycemia 1 2
Hypertension (new cases) 2 5
doi:10.1371/journal.pone.0001475.t003
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Table 4. Serious adverse events.
..................................................................................................................................................
Serious adverse event Placebo and omeprazole (n=25) Indomethacin and omeprazole (n=26)
Elevated creatinine
* 03
Abnormal liver function tests
{ 01
Stroke (lacunar) 0 1
Death 1 0
*.1.5 times the upper limit of normal.
{.3 times the upper limit of normal.
doi:10.1371/journal.pone.0001475.t004
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Indomethacin in Alzheimer’s
PLoS ONE | www.plosone.org 5 January 2008 | Issue 1 | e1475currently not be recommended, and further treatment trials with
NSAIDs in AD patients should be thoroughly reconsidered.
However, primary prevention trials with NSAIDs, in particular
ibuprofen (in combination with omeprazole), are warranted to
further investigate the effect of long-term NSAID use on risk of
AD.
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